VIVES is a multi-sector fund that invests in projects with a positive societal impact
Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane...
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
CISSOID is the leader in high temperature semiconductor solutions, delivering standard products and custom solutions for power management, power conversion and signal conditioning in extreme...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Denis Périquet, CEO Tessares:
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is